A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
L01-1409
NCT00056173
March 2002
Name | Location |
---|---|
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Ochsner Clinic Foundation | New Orleans, Louisiana 70121 |
SUNY Upstate Medical University | Syracuse, New York 13210 |
Innovative Medical Research of South Florida, Inc. | Miami, Florida 33138 |
University of Chicago Medical Center | Chicago, Illinois 60637 |
The Cleveland Clinic Foundation | Cleveland, Ohio |
Bay Area Cancer Research Group | Concord, California 94520 |
USC-Norris Comprehensive Cancer Center and Hospital | Los Angeles, California 90033 |
CA Hematology Oncology Medical Group | Torrance, California 90505 |
Comprehensive Cancer Center of Wake Forest University | Winston-Salem, North Carolina 27157-1082 |